middl
east
respiratori
syndrom
coronaviru
merscov
pose
seriou
threat
public
health
worldwid
caus
sever
respiratori
diseas
human
high
mortal
novemb
total
human
merscov
infect
death
report
countri
middl
east
north
africa
europ
asia
north
america
world
health
organ
report
kingdom
saudi
arabia
figur
http
wwwwhointemergenciesmerscoven
phylogenet
sequenc
data
strongli
suggest
merscov
belong
clineag
genu
betacoronaviru
first
known
lineag
c
betacoronaviru
associ
human
infect
clinic
featur
merscov
infect
rang
asymptomat
infect
rapidli
progress
acut
hypoxem
respiratori
failur
extrapulmonari
organ
dysfunct
present
effect
vaccin
therapeut
avail
prevent
treatment
merscov
infect
howev
mani
basic
clinic
studi
antimerscov
agent
complet
ongo
review
focu
current
progress
research
develop
smallmolecul
merscov
inhibitor
either
peptid
compound
target
differ
stage
merscov
life
cycl
aim
prevent
treat
merscov
infect
merscov
enter
host
cell
two
pathway
first
involv
plasma
membran
fusion
reli
spike
protein
activ
secret
surfac
proteas
transmembran
proteas
serin
human
airway
trypsinlik
proteas
hat
second
involv
endosom
membran
fusion
spike
protein
activ
facilit
phdepend
endosom
proteas
cathepsin
l
ctsl
spike
protein
play
key
role
merscov
attach
host
cell
viruscel
membran
fusion
contain
amino
acid
within
viral
envelop
trimer
state
spike
protein
consist
subunit
subunit
contain
receptor
bind
domain
rbd
subunit
contain
fusion
peptid
fp
long
heptad
repeat
domain
short
heptad
repeat
domain
merscov
enter
host
cell
bind
viral
particl
via
rbd
spike
protein
cellular
receptor
dipeptidyl
surfac
host
cell
chang
conform
insert
fp
plasma
membran
endosom
membran
virion
endosom
bind
form
sixhelix
bundl
fusion
core
bring
viral
cell
membran
close
apposit
fusion
process
rbd
relat
proteas
eg
hat
serv
target
develop
merscov
fusionentri
inhibitor
merscov
entri
host
cell
posit
rna
genom
translat
cytoplasm
genom
translat
two
polyprotein
ppla
pplb
cleav
nonstructur
protein
plpro
papainlik
proteas
proteas
henc
proteas
critic
import
merscov
replic
also
consid
target
develop
merscov
replic
inhibitor
howev
inform
enzym
requir
produc
genom
copi
subgenom
mrna
viru
replic
limit
rna
genom
structur
protein
packag
viral
particl
host
cell
progeni
viru
particl
final
releas
host
cell
figur
although
step
also
use
target
develop
merscov
maturationandreleas
inhibitor
inhibitor
report
far
merscov
protein
play
key
role
mediat
viru
entri
host
target
cell
process
includ
bind
host
receptor
viral
fusion
final
entri
host
cell
merscov
pseudoviru
express
protein
allow
singlecycl
infect
cell
express
receptor
use
screen
merscov
fusionentri
inhibitor
span
residu
domain
low
toxic
effect
vitro
effect
inhibit
merscov
replic
interact
domain
block
spike
proteinmedi
fusion
merscov
pseudoviru
entri
tabl
figur
increas
stabil
solubl
antimerscov
activ
lu
et
al
introduc
glu
ly
arg
residu
gener
new
peptid
tabl
inde
found
stabl
solubl
block
fusion
core
format
peptid
bind
viral
protein
domain
inhibit
proteinmedi
membran
fusion
figur
highli
effect
inhibit
merscov
infect
vero
cell
intranas
applic
could
significantli
reduc
titer
merscov
lung
adenoviru
dipeptidyl
peptidas
transduc
mice
furthermor
intranas
administr
viral
challeng
fulli
protect
mice
merscov
infect
wherea
untreat
mice
die
day
viral
challeng
furthermor
combin
interferon
protect
enhanc
mice
infect
merscov
strain
without
mutat
region
protein
reduct
viral
titer
lung
effect
fusion
inhibitor
merscov
inhibit
merscov
pseudoviru
infect
cell
cell
cell
count
assay
tabl
addit
seri
synthes
stapl
peptid
etc
could
effect
inhibit
infect
merscov
pseudoviru
spike
proteinmedi
cell
fusion
block
helixmedi
nhr
ntermin
heptad
repeat
chr
ctermin
heptad
repeat
interact
low
high
cell
short
peptid
exhibit
potent
broad
spectrum
antivir
effect
multipl
respiratori
virus
vitro
vivo
inhibit
merscov
madindarbi
canin
kidney
mdck
cell
obtain
plaqu
assay
mdck
cell
obtain
mtt
bromid
assay
tabl
lipopeptid
bioactiv
peptid
replic
chain
viral
fusion
machineri
lipopeptid
inhibit
fusion
mediat
merscov
protein
valu
rang
cell
tabl
among
lipopeptid
ll
ii
found
potent
merscov
fusion
inhibitor
valu
respect
lipopeptid
aa
ff
yy
iiy
iiw
iih
iiq
iik
iie
also
inhibit
fusion
mediat
merscov
protein
variabl
valu
three
neurotransmitt
inhibitor
includ
chlorpromazin
fluphenazin
promethazin
moder
inhibitor
fusion
valu
respect
tabl
figur
also
disrupt
clathrinmedi
endocytosi
inhibit
merscov
smallmolecul
hiv
entri
inhibitor
target
figur
concentr
could
inhibit
merscov
pseudoviru
infect
cell
could
interrupt
interact
merscov
form
sixhelix
bundl
thu
inhibit
entri
pseudotyp
merscov
cell
line
cell
mtt
assay
tabl
elucid
merscov
interact
host
cell
critic
develop
antivir
intervent
order
gain
entri
host
cell
merscov
use
function
viru
receptor
also
util
certain
cellular
proteas
member
cathepsin
famili
activ
glycoprotein
express
epitheli
cell
human
respiratori
gastrointestin
tract
respect
enzym
host
cell
also
excel
target
identif
smallmolecul
merscov
inhibitor
serin
proteas
inhibitor
camostat
mesyl
camostat
could
complet
block
syncytium
format
partial
block
viru
entri
vero
cell
figur
compound
known
inhibit
cruzain
cathepsinlik
proteas
protozoan
parasit
trypanosoma
cruzi
inhibit
merscov
nm
figur
chloroquin
inhibit
merscov
replic
block
infect
earli
step
tabl
figur
chlorpromazin
inhibit
merscov
replic
earli
postentri
stage
tabl
figur
howev
high
cytotox
narrow
therapeut
window
monocytederiv
macrophag
mdm
dendrit
cell
mddc
ouabain
bufalin
inhibit
merscov
entri
block
clathrinmedi
endocytosi
figur
addit
small
amount
ouabain
nm
bufalin
nm
inhibit
infect
merscov
vsv
vesicular
stomat
viru
tabl
drug
ad
prior
inocul
cell
dihydrotanshinon
lipophil
compound
show
decim
reduct
excel
antivir
effect
reduct
titer
log
log
use
pseudoviru
express
merscov
spike
protein
figur
biosynthesi
merscov
protein
furin
inhibitor
decanoylrvkrchloromethylketon
decrvkrcmk
lead
decreas
cleav
product
merscov
wt
mutant
figur
papainlik
proteas
cystein
proteas
use
thiol
group
cystein
nucleophil
attack
carbonyl
group
scissil
peptid
bond
genom
merscov
encod
two
polyprotein
ppla
pplb
process
papainlik
proteas
plpro
proteas
merscov
one
papainlik
proteas
sarscov
coronavirus
two
enzym
mersplpro
part
nonstructur
protein
includ
three
ubiquitinlik
domain
ubl
catalyt
triad
consist
ubiquitinbind
domain
ubd
zinc
homolog
model
mersplpro
multifunct
enzym
deisgyl
deubiquitin
dub
activ
also
block
interferon
regulatori
factor
pathway
disulfiram
drug
use
alcohol
avers
therapi
approv
us
food
drug
administr
fda
sinc
figur
inhibit
activ
enzym
ureas
methyltransferas
kinas
react
cystein
residu
suggest
broadspectrum
characterist
notabl
disulfiram
also
act
alloster
inhibitor
merscov
papainlik
proteas
multipl
inhibit
assay
also
support
kinet
mechan
disulfiram
togeth
andor
mpa
mycophenol
acid
synergist
inhibit
merscov
papainlik
proteas
henc
recombin
three
clinic
avail
drug
could
feasibl
use
treat
merscov
infect
activ
site
divid
subsit
subsit
consist
vital
catalyt
residu
process
polyprotein
conserv
gln
site
follow
small
amino
acid
like
ala
ser
gli
anoth
crucial
compon
subsit
oxyanion
hole
form
interact
carboxyl
anion
conserv
gln
stabil
transit
state
proteolysi
entranc
pocket
interact
via
hbond
conserv
gln
subsit
contain
hydrophob
bulki
side
chain
val
leu
phe
subsit
near
surfac
activ
site
littl
particip
substrat
bind
polyprotein
process
cleavag
site
plpro
cleavag
site
result
matur
nonstructur
protein
includ
rnadepend
rna
polymeras
rdrp
helicas
play
import
role
transcript
replic
coronavirus
therefor
proteas
essenti
viral
replic
make
attract
target
drug
develop
analogu
hit
neuraminidas
na
inhibitor
merscov
synthes
show
averagetogood
inhibit
better
one
compound
tabl
figur
anoth
two
compound
figur
figur
valu
repsect
tabl
furthermor
research
conclud
pharmacophor
phenyl
carboxyl
either
essenti
antivir
activ
sinc
modif
ring
b
well
toler
ring
alter
enhanc
activ
compound
sarscov
inhibitor
block
function
merscov
figur
treatment
inhibit
activ
merscov
dmsotreat
cell
maximum
dose
endpoint
evalu
indic
cell
cultur
tabl
peptidomimet
inhibitor
enteroviru
inhibit
merscov
valu
rang
shown
enzymat
assay
figur
shown
tabl
compound
effici
suppress
viral
replic
valu
respect
perform
cytopath
inhibit
assay
use
merscovinfect
cell
tabl
dipeptidyl
transit
state
inhibitor
substanti
inhibit
activ
merscov
fluoresc
reson
energi
transfer
fret
assay
tabl
figur
well
synthes
extend
compound
exhibit
inhibit
merscov
valu
cell
cultur
tabl
figur
broadspectrum
anticov
inhibitor
inhibit
proteolyt
activ
merscov
bind
interfac
domain
ii
merscov
tabl
figur
silvestrol
inhibitor
inhibit
merscov
infect
nm
shown
plaqu
assay
cell
nm
mtt
assay
peripher
blood
mononuclear
cell
pbmc
tabl
figur
silvestrol
broadspectrum
antivir
activ
via
inhibit
express
cov
structur
nonstructur
protein
n
format
viral
replicationtranscript
complex
combin
ribavirin
effect
reduc
merscov
replic
vitro
vivo
tabl
figur
rhesu
macaqu
treat
ribavirin
h
merscov
infect
show
improv
clinic
paramet
mild
radiograph
evid
pneumonia
compar
untreat
macaqu
moreov
treat
macaqu
show
lower
level
system
serum
local
lung
proinflammatori
marker
addit
fewer
viral
genom
copi
distinct
gene
express
less
sever
histopatholog
chang
lung
remdesivir
monophosphoramid
prodrug
cadenosin
nucleosid
analogu
inhibit
replic
model
murin
hepat
viru
mhv
rna
synthesi
wildtyp
wt
viru
exon
mutant
lack
proofread
demonstr
increas
suscept
figur
also
inhibit
merscov
infect
human
amniot
epitheli
hae
cell
tabl
furthermor
act
earli
postinfect
stage
decreas
viral
rna
level
wherea
delay
addit
h
postinfect
result
decreas
viral
titer
hae
cell
cultur
h
postinfect
nucleotid
analogu
also
inhibit
infect
merscov
hae
cell
tabl
figur
resveratrol
found
significantli
inhibit
merscov
infect
well
prolong
cellular
surviv
viru
infect
figur
found
resveratrol
could
reduc
rna
level
infect
titer
vero
cell
although
resveratrol
minim
cytotox
even
high
concentr
ignor
compar
much
sever
toxic
merscov
infect
seri
fdaapprov
compound
screen
merscov
tabl
cellbas
elisa
assay
figur
pharmaceut
inhibit
merscov
includ
neurotransmitt
inhibitor
estrogen
receptor
antagonist
kinas
signal
inhibitor
inhibitor
lipid
sterol
metabol
protein
process
inhibitor
inhibitor
dna
synthesisrepair
well
inhibitor
ion
transport
cytoskeleton
specif
tubulin
apoptosi
antiparasit
antibacteri
two
class
pharmaceut
function
obvious
link
coronavirus
virus
gener
nonetheless
show
antivir
activ
merscov
nocodazol
target
cytoskeleton
specif
interfer
microtubul
polymer
antimitot
drug
develop
treatment
cancer
found
show
high
activ
merscov
figur
monensin
salinomycin
sodium
two
nine
ion
channel
inhibitor
inhibitori
activ
merscov
indic
merscov
may
suscept
ionophor
activ
figur
chlorpromazin
chloroquin
appear
target
host
factor
rather
viral
protein
specif
treatment
viral
infect
patient
aim
host
factor
could
reconfigur
overt
manifest
viral
pathogenesi
less
virul
subclin
infect
lower
advers
diseas
outcom
figur
loperamid
antidiarrh
opioid
receptor
agonist
reduc
intestin
motil
also
inhibit
replic
merscov
lowmicromolar
concentr
vitro
tabl
figur
lopinavir
proteas
inhibitor
inhibit
merscov
replic
tabl
figur
inhibit
merscov
replic
vero
cell
tabl
figur
molecular
model
data
suggest
dock
compar
glide
score
reduc
viru
yield
inhibit
camp
signal
cell
typeindepend
manner
figur
concentr
merscov
inhibit
found
vero
cell
use
lactat
dehydrogenas
ldh
base
cytotox
assay
addit
undetect
cytopath
effect
cpe
minim
express
viral
antigen
indic
cell
treat
almost
fulli
protect
mycophenol
acid
mpa
strongli
reduc
merscov
replic
inhibit
inosin
monophosph
dehydrogenas
impdh
guanin
monophosph
synthesi
cellbas
elisa
vero
cell
tabl
figur
spectrum
inhibitor
inhibit
merscov
replic
reduc
format
doubl
membran
vesicl
dmv
nearcomplet
inhibit
rna
synthesi
figur
adenosin
analogu
act
nonoblig
rna
chain
termin
inhibit
viral
rna
polymeras
function
inhibit
merscov
infect
vero
cell
highli
charg
ion
hci
base
analysi
neutralr
uptak
tabl
figur
flexim
nucleosid
analogu
acyclovir
doubli
flexibl
nucleosid
analogu
base
acycl
sugar
scaffold
acyclovir
flexbas
moieti
flexim
respons
inhibit
rnadepend
rna
polymeras
rdrp
target
flexim
analogu
inhibit
merscov
infect
cell
vero
cell
tabl
figur
interferon
cyclosporin
csa
addit
synergist
effect
limit
merscov
replic
ex
vivo
cultur
human
bronchu
figur
addit
combin
treatment
csa
potent
effect
induc
interferonstimul
gene
isg
lung
hpi
bronchial
hpi
tissu
saracatinib
potent
inhibitor
srcfamili
tyrosin
kinas
sfk
potent
inhibit
merscov
cell
tabl
figur
possibl
inhibit
merscov
replic
suppress
sfk
signal
pathway
earli
stage
viral
life
cycl
addit
anoth
seven
compound
primarili
classifi
antiprotozo
anticanc
antipsychot
also
determin
complet
doserespons
analys
tabl
figur
spectruminhibitor
inhibit
merscov
interferoncompet
cell
line
cell
shown
mtt
assay
tabl
figur
luciferasebas
biosensor
assay
cellbas
screen
assay
select
merscovspecif
broadspectrum
coronaviru
plpro
inhibitor
cell
transfect
two
artifici
plasmid
proteas
express
plasmid
biosensor
express
plasmid
proteas
express
plasmid
contain
sequenc
merscov
plpro
nonstructur
protein
well
ntermin
region
biosensor
express
plasmid
contain
circularli
permut
photuri
pennsylvanica
luciferas
amino
sequenc
cleavag
site
plpro
cell
transfect
coexpress
merscov
proteas
domain
cleavageactiv
luciferas
substrat
transfect
live
cell
allow
endpoint
evalu
live
cell
imag
profil
proteas
activ
novel
method
perform
biosafeti
level
research
laboratori
evalu
abil
inhibit
cov
proteas
activ
exist
new
drug
pseudovirusbas
screen
assay
develop
identifi
antivir
compound
merscov
life
cycl
without
use
infecti
virus
merscov
pseudoviru
allow
singlecycl
infect
varieti
cell
express
result
consist
live
merscovbas
inhibit
assay
importantli
pseudoviru
assay
carri
rather
facil
vsv
hivluciferas
pseudotyp
merscov
protein
two
approach
structureguid
design
optim
small
molecul
strategi
involv
embodi
piperidin
moieti
design
element
attain
optim
pharmacolog
activ
protein
kinas
properti
strategi
permit
result
hybrid
inhibitor
particip
favor
bind
interact
subsit
attach
piperidin
moieti
dipeptidyl
compon
ubiquitinlik
domain
immedi
adjac
nterminu
plpro
domain
coronaviru
polyprotein
past
role
plpro
remain
undefin
howev
evid
indic
remov
domain
mer
plpro
effect
abil
process
viral
polyprotein
act
interferon
antagonist
involv
deubiquitin
deisgyl
cellular
protein
analyz
transcriptom
host
infect
merscov
provid
insight
merscov
infect
influenc
interact
host
cell
josset
et
al
infect
lung
epitheli
cell
line
merscov
analyz
transcriptom
identifi
inhibitori
compound
resid
host
factor
could
exploit
antivir
therapeut
approach
use
identifi
host
factor
benefici
viru
propag
thu
establish
appropri
target
exist
new
antivir
inhibitor
positivesens
singlestrand
rna
viru
merscov
util
host
cellular
compon
accomplish
variou
physiolog
process
includ
viral
entri
genom
replic
assembl
bud
virion
therebi
result
patholog
damag
host
therefor
variou
stage
viru
life
cycl
could
potenti
target
develop
smallmolecul
antivir
inhibitor
inhibitor
block
merscov
entri
host
cell
viral
proteas
inhibitor
inhibitor
target
host
cell
mani
smallmolecul
inhibitor
defin
undefin
mechan
action
summar
review
compound
interfer
viru
infect
may
harm
host
cell
therefor
establish
safeti
profil
essenti
furthermor
antivir
inhibitor
effect
inhibit
growth
viru
small
amount
virion
replic
lead
resist
mutat
advantag
smallmolecul
inhibitor
includ
low
price
stabil
conveni
oral
administr
three
main
approach
current
use
develop
merscov
smallmolecul
inhibitor
first
de
novo
synthesi
inhibitor
target
uniqu
structur
protein
merscov
appear
infect
process
second
approach
involv
screen
inhibitor
merscov
infect
exist
drug
databas
variou
chemic
synthesi
strategi
third
approach
involv
chang
chemic
group
fulli
develop
drug
enhanc
pharmacolog
activ
merscov
novel
strategi
improv
efficaci
screen
smallmolecul
inhibitor
anticip
reduc
threat
futur
merscov
infect
